VenatoRx Pharmaceuticals to Present at the 2019 BIO CEO & Investor Conference

VenatoRx Pharmaceuticals, a world leader in antibacterial and antiviral drug research and development, announced that its Chief Business Officer, Tony Meehan, MBA, PhD, will present at the 2019 BIO CEO & Investor Conference.

Presentation Details: Date: Monday, February 11, 2019 Time: 3:30pm ET Location: New York Marriott Marquis (Gramercy room)

About VenatoRx Pharmaceuticals, Inc.

VenatoRx is a private pharmaceutical company that is focused on the discovery and development of novel anti-infectives to treat multi-drug-resistant (MDR) bacterial infections and hard-to-treat viral infections. VenatoRxs lead product, VNRX-5133, is an injectable broad-spectrum beta-lactamase inhibitor (BLI) that directly inhibits all four Ambler classes of beta-lactamases. In addition, VenatoRx has a broad pipeline of preclinical programs, including a broad-spectrum orally bioavailable BLI, a novel class of Penicillin-Binding Protein (PBP) inhibitors that are impervious to beta-lactamase-driven resistance, and novel antiviral agents. For more information, please visit

Heather Hunter
Vice President, Communications
Pharmaceuticals, Inc.
[email protected]

ALSO READ:   Hilton Grand Vacations, Japan Airlines Announce an Expanded Partnership